{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T22:32:26Z","timestamp":1792103546962,"version":"4.4.0"},"reference-count":50,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2024,1,31]],"date-time":"2024-01-31T00:00:00Z","timestamp":1706659200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>(1) Background: Nivolumab plus chemotherapy is established as a first-line treatment for advanced gastric cancer (AGC). While mFOLFOX6 is commonly used for AGC with severe peritoneal metastasis, the efficacy of nivolumab combined with it remains uncertain. We evaluated the outcomes of nivolumab plus mFOLFOX6 for AGC with severe peritoneal metastasis in clinical practice. (2) Methods: This multicenter retrospective study was conducted between December 2021 and June 2023. We investigated AGC patients with massive ascites or inadequate oral intake due to severe peritoneal metastasis and who received nivolumab plus mFOLFOX6. (3) Results: Among 106 patients treated with nivolumab plus chemotherapy, 21 (19.8%) had severe peritoneal metastasis, with 14 receiving nivolumab plus mFOLFOX6. The median progression-free survival was 7.4 months (95%CI 1.9-10.1), and the median overall survival was 10.7 months (95%CI 5.3-NA), with four patients (28.5%) surviving more than 12 months. Improved ascites and oral intake were observed in 6\/14 patients (42.8%) and 10\/11 patients (90.9%), respectively. The major grade 3 or more adverse events included leukopenia (28.5%) and neutropenia (21.4%), with no severe immune-related adverse events reported. (4) Conclusions: The safety and moderate efficacy of nivolumab plus mFOLFOX6 were suggested even in AGC patients with severe peritoneal metastasis.<\/jats:p>","DOI":"10.3390\/jcm13030834","type":"journal-article","created":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T09:43:22Z","timestamp":1706780602000},"page":"834","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["The Efficacy and Safety of Nivolumab Plus mFOLFOX6 in Gastric Cancer with Severe Peritoneal Metastasis"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-8302-8466","authenticated-orcid":false,"given":"Yurika","family":"Nakayama","sequence":"first","affiliation":[{"name":"Third Department of Internal Medicine, University of Toyama, 2630 Sugitani, Toyama 930-0194, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayuki","family":"Ando","sequence":"additional","affiliation":[{"name":"Third Department of Internal Medicine, University of Toyama, 2630 Sugitani, Toyama 930-0194, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Takahashi","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Kouseiren Takaoka Hospital, 5-10 Eirakumachi, Takaoka-shi 933-8555, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenichiro","family":"Tsukada","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Kouseiren Takaoka Hospital, 5-10 Eirakumachi, Takaoka-shi 933-8555, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroaki","family":"Takagi","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Toyama Prefectural Central Hospital, 2-2-78 Nishinagae, Toyama-shi 930-8550, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuno","family":"Goto","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Takaoka City Hospital, 4-1 Takaramachi, Takaoka-shi 933-8550, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsuko","family":"Nakaya","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Takaoka City Hospital, 4-1 Takaramachi, Takaoka-shi 933-8550, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naokatsu","family":"Nakada","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Itoigawa General Hospital, 457-1 Takegahana, Itoigawa-shi 941-8502, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Yoshita","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Toyama Nishi General Hospital, 1019 Fuchumachi Shimokutsuwada, Toyama-shi 939-2716, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iori","family":"Motoo","sequence":"additional","affiliation":[{"name":"Third Department of Internal Medicine, University of Toyama, 2630 Sugitani, Toyama 930-0194, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Ueda","sequence":"additional","affiliation":[{"name":"Third Department of Internal Medicine, University of Toyama, 2630 Sugitani, Toyama 930-0194, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuko","family":"Ueda","sequence":"additional","affiliation":[{"name":"Third Department of Internal Medicine, University of Toyama, 2630 Sugitani, Toyama 930-0194, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miho","family":"Sakumura","sequence":"additional","affiliation":[{"name":"Third Department of Internal Medicine, University of Toyama, 2630 Sugitani, Toyama 930-0194, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinya","family":"Kajiura","sequence":"additional","affiliation":[{"name":"Third Department of Internal Medicine, University of Toyama, 2630 Sugitani, Toyama 930-0194, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kohei","family":"Ogawa","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Toyama Prefectural Central Hospital, 2-2-78 Nishinagae, Toyama-shi 930-8550, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayumu","family":"Hosokawa","sequence":"additional","affiliation":[{"name":"Department of Clinical Oncology, University of Miyazaki Hospital, Kihara-5200 Kiyotakecho, Miyazaki-shi 889-1692, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6888-0310","authenticated-orcid":false,"given":"Ichiro","family":"Yasuda","sequence":"additional","affiliation":[{"name":"Third Department of Internal Medicine, University of Toyama, 2630 Sugitani, Toyama 930-0194, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,1,31]]},"reference":[{"key":"ref_1","unstructured":"International Agency for Research on Cancer (2023, June 19). Globocan 2020. Available online: http:\/\/gco.iarc.fr\/today."},{"key":"ref_2","unstructured":"Research FfPoC (2023, June 19). Cancer Statistics in Japan. Available online: https:\/\/ganjoho.jp\/public\/qa_links\/report\/statistics\/2022_en.html."},{"key":"ref_3","unstructured":"International Agency for Research on Cancer (2023, June 19). Helicobacter pylori. IARC Monographs. Available online: https:\/\/monographs.iarc.who.int\/wp-content\/uploads\/2018\/06\/mono100B-15.pdf."},{"key":"ref_4","first-page":"26","article-title":"Epidemiology of gastric cancer: Global trends, risk factors and prevention","volume":"14","author":"Rawla","year":"2019","journal-title":"Prz. Gastroenterol."},{"key":"ref_5","unstructured":"GBD 2017 Stomach Cancer Collaborators (2020). The global, regional, and national burden of stomach cancer in 195 countries, 1990\u20132017: A systematic analysis for the global burden of disease study 2017. Lancet Gastroenterol. Hepatol., 5, 42\u201354."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/S0140-6736(17)33326-3","article-title":"Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): Analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries","volume":"391","author":"Allemani","year":"2018","journal-title":"Lancet"},{"key":"ref_7","first-page":"122","article-title":"Advanced gastric cancer in Jordan from 2004 to 2008: A study of epidemiology and outcomes","volume":"4","author":"Abbasi","year":"2011","journal-title":"Gastrointest. Cancer Res."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1002\/ijc.28373","article-title":"Peritoneal carcinomatosis of gastric origin: A population-based study on incidence, survival and risk factors","volume":"134","author":"Thomassen","year":"2014","journal-title":"Int. J. Cancer."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1016\/S1470-2045(09)70259-1","article-title":"Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: A randomized phase 3 study","volume":"10","author":"Boku","year":"2009","journal-title":"Lancet Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/S1470-2045(08)70035-4","article-title":"S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): A phase III trial","volume":"9","author":"Koizumi","year":"2008","journal-title":"Lancet Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1093\/annonc\/mdu472","article-title":"Phase III study comparing oxaliplatin plus S-1 with cisplatin plus S-1 in chemotherapy-na\u00efve patients with advanced gastric cancer","volume":"26","author":"Yamada","year":"2015","journal-title":"Ann. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1093\/jjco\/hyt114","article-title":"Randomized phase III study of 5-fluorouracil continuous infusion vs. sequential methotrexate and 5-fluorouracil therapy in far advanced gastric cancer with peritoneal metastasis (JCOG0106)","volume":"43","author":"Shirao","year":"2013","journal-title":"Jpn. J. Clin. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1093\/jjco\/hys111","article-title":"Multicenter feasibility study of combination therapy with fluorouracil, leucovorin and paclitaxel (FLTAX) for peritoneal disseminated gastric cancer with massive ascites or inadequate oral intake","volume":"42","author":"Iwasa","year":"2012","journal-title":"Jpn. J. Clin. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1007\/s10120-020-01043-x","article-title":"Randomized phase II\/III study of 5-fluorouracil\/l-leucovorin versus 5-fluorouracil\/l-leucovorin plus paclitaxel administered to patients with severe peritoneal metastases of gastric cancer (JCOG1108\/WJOG7312G)","volume":"23","author":"Nakajima","year":"2020","journal-title":"Gastric. Cancer"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"425","DOI":"10.3892\/ol.2011.496","article-title":"Oxaliplatin, 5-fluorouracil and leucovorin (modified FOLFOX-6) as first-line chemotherapy for advanced gastric cancer patients with poor performance status","volume":"3","author":"Kim","year":"2012","journal-title":"Oncol. Lett."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"4011","DOI":"10.1200\/jco.2013.31.15_suppl.4011","article-title":"Vismodegib, a hedgehog pathway inhibitor, combined with FOLFOX for first-line therapy of patients with advanced gastric and gastroesophageal junction carcinoma: A New York cancer Consoritum led phase II randomized study","volume":"31","author":"Cohen","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1634\/theoncologist.2016-0038","article-title":"A randomized phase II study of FOLFOX with or without the MET inhibitor Onartuzumab in advanced adenocarcinoma of the stomach and gastroesophageal junction","volume":"21","author":"Shah","year":"2016","journal-title":"Oncologist"},{"key":"ref_19","first-page":"57","article-title":"Ramucirumab combined with FOLFOX as front-line therapy for advanced esophageal, gastroesophageal junction, or gastric adenocarcinoma: A retrospective study","volume":"16","author":"Yoon","year":"2011","journal-title":"Int. J. Clin. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1093\/jjco\/hym131","article-title":"A phase II study of oxaliplatin with low-dose leucovorin and bolus and continuous infusion 5-fluorouracil (modified FOLFOX-4) for gastric cancer patients with malignant ascites","volume":"37","author":"Oh","year":"2007","journal-title":"Jpn. J. Clin. Oncol."},{"key":"ref_21","first-page":"7037","article-title":"FOLFOX as first-line therapy for gastric cancer with severe peritoneal metastasis","volume":"37","author":"Masuishi","year":"2017","journal-title":"Anticancer Res."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"8301","DOI":"10.2147\/OTT.S184665","article-title":"Modified FOLFOX6 as a first-line treatment for patients with advanced gastric cancer with massive ascites or inadequate oral intake","volume":"11","author":"Osumi","year":"2018","journal-title":"Onco. Targets Ther."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/S1470-2045(21)00692-6","article-title":"Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): A randomised, multicentre, double-blind, placebo-controlled, phase 3 trial","volume":"23","author":"Kang","year":"2022","journal-title":"Lancet Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0140-6736(21)00797-2","article-title":"First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): A randomised, open-label, phase 3 trial","volume":"398","author":"Janjigian","year":"2021","journal-title":"Lancet"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1038\/onc.2009.356","article-title":"Immunogenic death of colon cancer cells treated with oxaliplatin","volume":"29","author":"Tesniere","year":"2010","journal-title":"Oncogene"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1703449","DOI":"10.1080\/2162402X.2019.1703449","article-title":"Trial watch: Chemotherapy-induced immunogenic cell death in immune-oncology","volume":"9","author":"Vanmeerbeek","year":"2020","journal-title":"Oncoimmunology"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"179","DOI":"10.4161\/onci.1.2.19026","article-title":"Trial watch: Chemotherapy with immunogenic cell death inducers","volume":"1","author":"Vacchelli","year":"2012","journal-title":"Oncoimmunology"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1038\/s41467-018-04605-x","article-title":"Synergistic and how adverse effect cancer immunotherapy by immunogenic chemotherapy and locally expressed PD-L1 trap","volume":"9","author":"Song","year":"2018","journal-title":"Nat. Commun."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1053\/j.gastro.2020.10.036","article-title":"PD-1 signaling promotes tumor-infiltrating myeloid-derived suppressor cells and gastric tumorigenesis in mice","volume":"160","author":"Kim","year":"2021","journal-title":"Gastroenterology"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1007\/s13402-020-00552-2","article-title":"Oxaliplatin induces immunogenic cell death in hepatocellular carcinoma cells and synergizes with immune checkpoint blockade therapy","volume":"43","author":"Zhu","year":"2020","journal-title":"Cell Oncol."},{"key":"ref_31","unstructured":"(2023, June 19). Clinical Practice Guidelines for Peritoneal Malignancy 2021. (In Japanese)."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1200\/JCO.21.01862","article-title":"Low programmed death-ligand 1-expressing subgroup outcomes of first-line immune checkpoint inhibitors in gastric or esophageal adenocarcinoma","volume":"40","author":"Zhao","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1001\/jamaoncol.2022.3707","article-title":"Association of PD-L1 expression and other variables with benefit from immune checkpoint inhibition in advanced gastroesophageal cancer: Systematic review and meta-analysis of 17 phase 3 randomized clinical trials","volume":"8","author":"Yoon","year":"2022","journal-title":"JAMA Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1007\/s00280-022-04479-3","article-title":"Distribution of therapeutic monoclonal antibodies into ascites in advanced gastric cancer patients with peritoneal metastasis: Case reports and literature review","volume":"90","author":"Kaneko","year":"2022","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"e004001","DOI":"10.1136\/jitc-2021-004001","article-title":"Ascites and resistance to immune checkpoint inhibition in dMMR\/MSI-H metastatic colorectal and gastric cancer","volume":"10","author":"Cohen","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1515\/pp-2017-0010","article-title":"Pharmacological principles of intraperitoneal and bidirectional chemotherapy","volume":"2","author":"Michelakis","year":"2017","journal-title":"Pleura Peritoneum."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"e004749","DOI":"10.1136\/jitc-2022-004749","article-title":"Resistance to systemic immune checkpoint inhibition in the peritoneal niche","volume":"10","author":"Chia","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1186\/s40425-019-0590-4","article-title":"Treatment of malignant pleural effusions: The case for localized immunotherapy","volume":"7","author":"Donnenberg","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.immuni.2019.05.010","article-title":"A stromal niche defined by expression of the transcription factor WT1 mediates programming and homeostasis of cavity-resident macrophages","volume":"51","author":"Buechler","year":"2019","journal-title":"Immunity"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1186\/s40425-019-0708-8","article-title":"Comprehensive immune profiling and immune-monitoring using body fluid of patients with metastatic gastric cancer","volume":"7","author":"Park","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"e005345","DOI":"10.1136\/jitc-2022-005345","article-title":"Modeling resistance of colorectal peritoneal metastases to immune checkpoint blockade in humanized mice","volume":"10","author":"Heesters","year":"2022","journal-title":"J. Immuno Ther. Cancer"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/j.ccell.2021.05.006","article-title":"Tim-4+ cavity-resident macrophage impair anti-tumor CD8+ T cell immunity","volume":"39","author":"Chow","year":"2021","journal-title":"Cancer Cell"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1093\/jjco\/hyx044","article-title":"Survival after failure of first-line chemotherapy in advanced gastric cancer patients: Differences between Japan and the rest of the world","volume":"47","author":"Takashima","year":"2017","journal-title":"Jpn. J. Clin. Oncol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"4987","DOI":"10.21873\/anticanres.13688","article-title":"Previous immune checkpoint inhibitor treatment to increase the efficacy of docetaxel and ramucirumab combination chemotherapy","volume":"39","author":"Harada","year":"2019","journal-title":"Anticancer. Res."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1097\/PPO.0000000000000327","article-title":"Combinations of bevacizumab with cancer immunotherapy","volume":"24","author":"Chen","year":"2018","journal-title":"Cancer J."},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Zhou, X., Yao, Z., Yang, H., Liang, N., Zhang, X., and Zhang, F. (2020). Are immune-related adverse events associated with the efficacy of immune checkpoint inhibitors in patients with cancer? A systematic review and meta-analysis. BMC Med., 18.","DOI":"10.1186\/s12916-020-01549-2"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"2730","DOI":"10.1200\/JCO.19.00318","article-title":"Analysis of the association between adverse events and outcome in patients receiving a programmed death protein 1 or programmed death ligand 1 antibody","volume":"37","author":"Maher","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1186\/s40425-019-0805-8","article-title":"Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors","volume":"7","author":"Das","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"257","DOI":"10.2217\/imt-2020-0179","article-title":"Immortal time bias in the association between toxicity and response for immune checkpoint inhibitors: A meta-analysis","volume":"13","author":"Rizzo","year":"2021","journal-title":"Immunotherapy"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"475","DOI":"10.21873\/invivo.12281","article-title":"Prognosis of immune-related adverse events in patients with advanced gastric cancer treated with nivolumab or pembrolizumab: A multicenter retrospective analysis","volume":"35","author":"Ando","year":"2021","journal-title":"Vivo"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/13\/3\/834\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T13:52:46Z","timestamp":1760104366000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/13\/3\/834"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,31]]},"references-count":50,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2024,2]]}},"alternative-id":["jcm13030834"],"URL":"https:\/\/doi.org\/10.3390\/jcm13030834","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,31]]}}}